Navigation Links
Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas
Date:7/7/2010

llular openings to tumor cells and ease the delivery of drugs, such as chemotherapies. In this study, however, the researchers discovered that bevacizumab has to be given after the virus to maximize the anti-tumor effect of the combined therapy. In fact, giving bevacizumab first lowered the virus's uptake in cancer cells.

The rRp450 oncolytic virus used in the study was derived from herpes simplex type 1. The virus was genetically modified by scientists by removing a gene that makes the virus unable to replicate efficiently in dormant cells. This causes the virus to selectively target and replicate in rapidly growing cancer cells while leaving normally dormant healthy tissue cells alone.

After removing the one gene from the virus, researchers replaced it with a gene that encodes an enzyme that activates a class of anti-tumor chemotherapies called oxazaphosphorines. The overall therapeutic approach is for the virus to infect and degrade the cancer cells and then activate chemotherapy agents as anti-angiogenic agents cut off vascular growth and blood supply to the tumors.

In the current study, however, researchers treated the mice only with rRp450 and the anti-angiogenic drug bevacizumab. This allowed them to test whether the virus could be given systemically, how anti-angiogenic drugs affected virus tumor uptake and the impact this had on tumor growth.

In mice receiving bevacizumab prior to the rRp450, overall tumor shrinkage averaged 40 percent. In mice receiving rRp450 before bevacizumab, tumor size was reduced by an average of 75 percent. The researchers also reported that mice treated with rRp450 before bevacizumab had longer survival rates.

Results of the current study could be used immediately to help design subsequent research into treatment protocols for oncolytic viruses, particularly clinical trials
'/>"/>

SOURCE Cincinnati Children's Hospital Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
2. Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes
3. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
4. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
5. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
6. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
7. Data From LigoCytes Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research
8. Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk
9. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
10. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
11. Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 New technology in ... could allow physicians to see and assess brain tissue ... according to study authors who released their findings today ... Annual Meeting in Colorado Springs, CO. ... the field of neurointervention, a specialty that facilitates stroke ...
(Date:7/29/2014)... 2014 McGraw-Hill Education Professional, a leading global ... and medical communities, has announced the launch of the ... of the world-renowned medical education platform. ... , available for download onto all iOS and Android ... gain access to valuable AccessMedicine diagnostic resources ...
(Date:7/29/2014)... CITY and TORONTO ... EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging ... the development of improved novel formulations and ... molecules announces expansion of its pharmaceutical development ... development direction includes large molecule drugs that will ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4
... Seen Since Presentation at ASCO ... Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, Calif., Sept. ... a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 inhibitor,demonstrated antitumor ...
... Sept. 7 Roche announced today that three,clinical data ... for presentation at the 2007 Breast Cancer Symposium in ... abstracts include data from the XeNA (Xeloda in NeoAdjuvant),trial, ... Herceptin in,patients with invasive breast cancer. The third presentation ...
Cached Medicine Technology:Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 2Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 3
(Date:7/29/2014)... have discovered a chemical alteration in a single human ... larger studies, could give doctors a simple blood test ... , The discovery, described online in The American ... gene involved in the function of the brain,s response ... what might otherwise be an unremarkable reaction to the ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... Daily Gossip reveals in its Leaky Gut Cure ... and functional medicine practitioner, who spent years looking for a ... suffered from leaky gut, too, so this is what determined ... treatment. , Karen Brimeyer decided to share her story, ... the world. The author of the Leaky Gut Cure program ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... protecting the rights of victims injured by defective drugs ... has been filed by plaintiffs in Canada who allege ... of cardiovascular events with the low testosterone injection ... on July 22, 2014 in the Ontario Superior Court ...
(Date:7/29/2014)... 29, 2014 Daily Gossip reveals in its ... holistic system that will permanently eliminate all the symptoms associated ... natural treatment will banish symptoms such as mild hearing loss, ... heard by patients will be gone forever. , The method ... The author of this program says that at the end ...
Breaking Medicine News(10 mins):Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2
... regulators told a Congressional panel today that some biological ... -- are simple enough// to produce in generic versions, ... ,Generic versions of certain biologics have been ... approval came only after manufacturers conducted rigorous human clinical ...
... of governments of Western Pacific countries in fighting tuberculosis (TB), ... control the disease. ,The region has successfully met ... of TB cases and curing at least 85 percent of ... body's TB programme. ,He was speaking at a ...
... Researchers from the decades long Framingham Heart Study, say that if ... there is a good chance// of you having lessened the risk ... continue, if your parents died young, diet and exercise may well ... published in the Archives of Internal Medicine, show that middle-aged children ...
... of industrial chemicals has suggested that we may not ... prolonged use of non-stick frying// pans and baking trays; ... penetrate into our system causing health problems, they said. ... Notification and Assessment Scheme or NICNAS said it is ...
... mattresses and TVs contain possibly hazardous chemicals called polybrominated ... National Institute of Standards and Technology and the Environmental ... ,It is not yet clear how dangerous these PBDEs ... of Europe. Their structure is strikingly similar to that ...
... soldiers who are suffering from mental illness after serving ... 18 months or longer for treatment// from the National ... figures released by British Ministry of Defence (MoD) showed ... health conditions after returning from Iraq since 2003. More ...
Cached Medicine News:Health News:Caution Urged on Biologic Drugs 2Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Take Heart If Your Parents Died at a Ripe Old Age: Framingham Heart Study 2
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F....
... The all-new Canon CF-60DSi is an all-digital ... simple configuration, and an efficient workflow. ... mounts -- The Canon EOS-1Ds series SLR digital ... a 11.1 mega pixel resolution and the new ...
... The AIA-360 is a sophisticated Aumated Immunoassay ... This analyzer has a footprint of 16 X ... lbs. Its compact design is ideal for ... STAT testing, such as cardiac panels, as well ...
... a simple one, help physicians serve their ... the physician is provided with significantly useful ... This technical accomplishment is combined with dedicated ... The device features: High ...
Medicine Products: